Eli Lilly and Company $LLY is Bahl & Gaynor Inc.’s 6th Largest Position

Bahl & Gaynor Inc. reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 803,980 shares of the company’s stock after selling 27,509 shares during the quarter. Eli Lilly and Company makes up 3.0% of Bahl & Gaynor Inc.’s portfolio, making the stock its 6th biggest holding. Bahl & Gaynor Inc. owned approximately 0.09% of Eli Lilly and Company worth $613,437,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. RFP Financial Group LLC increased its stake in shares of Eli Lilly and Company by 10.8% during the 3rd quarter. RFP Financial Group LLC now owns 1,032 shares of the company’s stock valued at $795,000 after acquiring an additional 101 shares during the last quarter. Ted Buchan & Co grew its holdings in Eli Lilly and Company by 5.2% in the third quarter. Ted Buchan & Co now owns 3,922 shares of the company’s stock valued at $2,992,000 after purchasing an additional 195 shares during the period. Accent Capital Management LLC increased its position in Eli Lilly and Company by 1.2% during the third quarter. Accent Capital Management LLC now owns 5,814 shares of the company’s stock worth $4,436,000 after purchasing an additional 67 shares during the last quarter. River Wealth Advisors LLC raised its stake in Eli Lilly and Company by 10.9% during the third quarter. River Wealth Advisors LLC now owns 12,316 shares of the company’s stock worth $9,397,000 after purchasing an additional 1,213 shares during the period. Finally, Bedell Frazier Investment Counselling LLC boosted its holdings in shares of Eli Lilly and Company by 2.1% in the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 9,839 shares of the company’s stock valued at $7,507,000 after purchasing an additional 198 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 2.8%

NYSE LLY opened at $1,050.39 on Monday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The business has a 50 day moving average price of $1,053.15 and a two-hundred day moving average price of $931.94. The stock has a market cap of $990.90 billion, a PE ratio of 45.77, a P/E/G ratio of 1.22 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the previous year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Topline ACHIEVE‑3 results for type 2 diabetes showed meaningful A1C and weight benefits for Lilly’s oral GLP‑1 in a head‑to‑head setting, reinforcing the drug’s commercial and regulatory potential. Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
• Positive Sentiment: Detailed Phase 3/Lancet results show orforglipron outperformed oral semaglutide on A1C and weight in ACHIEVE‑3, strengthening Lilly’s case for market share and supporting upcoming regulatory timelines (U.S. obesity decision possible in Q2). Orforglipron Lancet results PR Newswire
• Positive Sentiment: CHMP issued a positive opinion for expanded EU use of Olumiant (baricitinib) in adolescents with severe alopecia areata — a near‑term regulatory win that expands labeled indications and revenue opportunities in Europe. Olumiant CHMP positive opinion PR Newswire
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $1,250 PT, signaling institutional confidence in Lilly’s obesity leadership; coupled with recent price‑target increases from other shops, this boosts investor conviction. RBC Capital initiates Eli Lilly
• Positive Sentiment: High‑profile media/TV endorsements (e.g., Jim Cramer recommending Lilly over Novo Nordisk) are supportive for retail flows and sentiment toward LLY. Jim Cramer Recommends Eli Lilly
• Neutral Sentiment: Reuters published additional trial safety data giving a more detailed picture of side effects — useful context for regulators and investors but not a clear negative or positive on balance. Reuters: additional data on weight-loss pill
• Neutral Sentiment: Health‑care stocks broadly moved higher today, which can amplify sector leaders’ moves but may reflect macro/flow dynamics rather than company‑specific fundamentals. Sector Update: Health Care Stocks Higher
• Negative Sentiment: Smaller rivals (e.g., Viking Therapeutics) and other entrants remain active in the obesity space — a potential long‑term competitive risk that could pressure pricing and market share over time. Viking Therapeutics profile

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. TD Cowen boosted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Daiwa Securities Group raised their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.